Cystatin C and Cardiovascular Risk
Open Access
- 1 November 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 55 (11), 1932-1943
- https://doi.org/10.1373/clinchem.2009.128397
Abstract
Background: Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular disease (CVD) and cardiovascular events. Cystatin C, a protease inhibitor synthesized in all nucleated cells, has been proposed as a replacement for serum creatinine for the assessment of renal function, particularly to detect small reductions in glomerular filtration rate.This publication has 62 references indexed in Scilit:
- Impact of Kidney Disease and Blood Pressure on the Development of Cardiovascular DiseaseCirculation, 2008
- Prevalence of Chronic Kidney Disease in the United StatesJAMA, 2007
- Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial InfarctionThe New England Journal of Medicine, 2004
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equationsLiver Transplantation, 2004
- Kidney Disease as a Risk Factor for Development of Cardiovascular DiseaseCirculation, 2003
- Estimation of Glomerular Filtration Rate in Older Patients with Chronic Renal Insufficiency: Is the Modification of Diet in Renal Disease Formula an Improvement?Journal of the American Geriatrics Society, 2003
- Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiencyKidney International, 2002
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976